SE436885B - Nya kvartera salter av 3-amino-17a-aza-d-homoandrostan-derivat och forfarande for framstellning derav - Google Patents
Nya kvartera salter av 3-amino-17a-aza-d-homoandrostan-derivat och forfarande for framstellning deravInfo
- Publication number
- SE436885B SE436885B SE7808703A SE7808703A SE436885B SE 436885 B SE436885 B SE 436885B SE 7808703 A SE7808703 A SE 7808703A SE 7808703 A SE7808703 A SE 7808703A SE 436885 B SE436885 B SE 436885B
- Authority
- SE
- Sweden
- Prior art keywords
- aza
- homo
- methyl
- general formula
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 4
- -1 dimethyl iodide Chemical compound 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical group 0.000 claims description 5
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- GFGAOQYLPGMLRJ-UHFFFAOYSA-N CBrC Chemical compound CBrC GFGAOQYLPGMLRJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000012022 methylating agents Substances 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- 230000008018 melting Effects 0.000 description 17
- 238000002844 melting Methods 0.000 description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000009835 boiling Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940102396 methyl bromide Drugs 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229940120904 succinylcholine chloride Drugs 0.000 description 6
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- PDNBZMXDIQRBBZ-KMYXDLQKSA-L (4as,4br,6as,8r,10as,10bs,12as)-1,1,10a,12a-tetramethyl-8-(1-methylpyrrolidin-1-ium-1-yl)-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-tetradecahydro-2h-naphtho[2,1-f]quinolin-1-ium;dibromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2CC[C@]3([C@H](C2)CC[C@H]2[C@H]4[C@]([N+](CCC4)(C)C)(C)CC[C@H]32)C)CCCC1 PDNBZMXDIQRBBZ-KMYXDLQKSA-L 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- GGAGIPMNQXAXNH-XDMKMBKMSA-L candocuronium iodide Chemical compound [I-].[I-].C[N+]1([C@H]2CC[C@]3(C(C2)=CC[C@H]2[C@H]4[C@]([N+](CCC4)(C)C)(C)CC[C@H]32)C)CCCC1 GGAGIPMNQXAXNH-XDMKMBKMSA-L 0.000 description 3
- 230000002999 depolarising effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 2
- 240000003801 Sigesbeckia orientalis Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FSWZJUFTIKBELK-ZVZPGWEDSA-N (3as,3br,9as,9bs,11as)-1-ethyl-9a,11a-dimethyl-2,3,3a,3b,4,5,5a,6,7,8,9,9b,10,11-tetradecahydronaphtho[2,1-e]indole Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCN(CC)[C@@]1(C)CC2 FSWZJUFTIKBELK-ZVZPGWEDSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GIVYFVIMRNKEAR-QQSRUBQLSA-N C[C@](CCC1)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CCCC2)[C@H]2CC1.Br.Br Chemical compound C[C@](CCC1)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CCCC2)[C@H]2CC1.Br.Br GIVYFVIMRNKEAR-QQSRUBQLSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012971 dimethylpiperazine Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63H—TOYS, e.g. TOPS, DOLLS, HOOPS OR BUILDING BLOCKS
- A63H1/00—Tops
- A63H1/32—Whirling or spinning discs driven by twisted cords
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU77RI644A HU175287B (hu) | 1977-08-18 | 1977-08-18 | Sposob poluchenija novykh proizvodnykh 3-amino-17al'fa-aza-d-gomo-androstana,dalee ikh kislotoaddicionnykh i chetvjortichnykh solej |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7808703L SE7808703L (sv) | 1979-02-19 |
| SE436885B true SE436885B (sv) | 1985-01-28 |
Family
ID=11001041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7808703A SE436885B (sv) | 1977-08-18 | 1978-08-16 | Nya kvartera salter av 3-amino-17a-aza-d-homoandrostan-derivat och forfarande for framstellning derav |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4200636A (cs) |
| JP (1) | JPS5448799A (cs) |
| AT (1) | AT364096B (cs) |
| AU (1) | AU519292B2 (cs) |
| BE (1) | BE869834A (cs) |
| CA (1) | CA1110229A (cs) |
| CS (1) | CS208658B2 (cs) |
| DD (1) | DD138323A5 (cs) |
| DE (1) | DE2835987A1 (cs) |
| DK (1) | DK363278A (cs) |
| FR (1) | FR2400525A1 (cs) |
| GB (1) | GB2003479B (cs) |
| HU (1) | HU175287B (cs) |
| IL (1) | IL55352A0 (cs) |
| NL (1) | NL190704C (cs) |
| PL (1) | PL113864B1 (cs) |
| SE (1) | SE436885B (cs) |
| YU (1) | YU40920B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5140022A (en) * | 1990-10-01 | 1992-08-18 | Anaquest, Inc. | 3-acyclic or cyclicaminomethyl-17a-lower-alkyl-17a-aza-d-homo-5-alpha-androstanes |
| US5229511A (en) * | 1990-10-01 | 1993-07-20 | Anaquest, Inc. | 3-substituted-aminomethyl-3-substituted-oxy-17A-methyl-17A-lower-alkyl-17A-aza-d-homo-5-alpha-androstanes |
| GB2331988B (en) * | 1997-12-04 | 2003-04-16 | Imperial College | Polycyclic sulphamate inhibitors or oestrone sulphatase |
| ES2258174T3 (es) | 2001-10-18 | 2006-08-16 | Sterix Limited | Compuestos esteroideos para la inhibicion de la sulfatasa esteroidea. |
| WO2016084790A1 (ja) * | 2014-11-25 | 2016-06-02 | 第一三共株式会社 | ヒドロナフトキノリン誘導体 |
-
1977
- 1977-08-18 HU HU77RI644A patent/HU175287B/hu not_active IP Right Cessation
-
1978
- 1978-08-14 IL IL7855352A patent/IL55352A0/xx not_active IP Right Cessation
- 1978-08-16 SE SE7808703A patent/SE436885B/sv not_active IP Right Cessation
- 1978-08-16 CS CS785347A patent/CS208658B2/cs unknown
- 1978-08-16 AU AU38966/78A patent/AU519292B2/en not_active Expired
- 1978-08-17 NL NL7808543A patent/NL190704C/xx not_active IP Right Cessation
- 1978-08-17 DK DK363278A patent/DK363278A/da not_active Application Discontinuation
- 1978-08-17 DD DD78207348A patent/DD138323A5/xx unknown
- 1978-08-17 YU YU1970/78A patent/YU40920B/xx unknown
- 1978-08-17 US US05/934,799 patent/US4200636A/en not_active Expired - Lifetime
- 1978-08-17 AT AT0597078A patent/AT364096B/de not_active IP Right Cessation
- 1978-08-17 FR FR7824030A patent/FR2400525A1/fr active Granted
- 1978-08-17 CA CA309,516A patent/CA1110229A/en not_active Expired
- 1978-08-17 DE DE19782835987 patent/DE2835987A1/de not_active Withdrawn
- 1978-08-18 BE BE189956A patent/BE869834A/xx not_active IP Right Cessation
- 1978-08-18 JP JP10012778A patent/JPS5448799A/ja active Pending
- 1978-08-18 GB GB7833925A patent/GB2003479B/en not_active Expired
- 1978-08-18 PL PL1978209122A patent/PL113864B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2400525B1 (cs) | 1982-06-11 |
| GB2003479B (en) | 1982-05-26 |
| FR2400525A1 (fr) | 1979-03-16 |
| DD138323A5 (de) | 1979-10-24 |
| ATA597078A (de) | 1981-02-15 |
| CS208658B2 (en) | 1981-09-15 |
| AU519292B2 (en) | 1981-11-19 |
| JPS5448799A (en) | 1979-04-17 |
| CA1110229A (en) | 1981-10-06 |
| SE7808703L (sv) | 1979-02-19 |
| PL113864B1 (en) | 1981-01-31 |
| YU40920B (en) | 1986-08-31 |
| AU3896678A (en) | 1980-02-21 |
| US4200636A (en) | 1980-04-29 |
| HU175287B (hu) | 1980-06-28 |
| NL190704C (nl) | 1994-07-01 |
| DE2835987A1 (de) | 1979-03-01 |
| DK363278A (da) | 1979-02-19 |
| BE869834A (fr) | 1978-12-18 |
| NL7808543A (nl) | 1979-02-20 |
| PL209122A1 (pl) | 1979-06-04 |
| IL55352A0 (en) | 1978-10-31 |
| GB2003479A (en) | 1979-03-14 |
| AT364096B (de) | 1981-09-25 |
| YU197078A (en) | 1982-10-31 |
| NL190704B (nl) | 1994-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL49786A (en) | Furo(orthieno)(3,2-c)pyridinium derivatives their preparation and pharmaceutical compositions containing them | |
| US3987177A (en) | Vincaminic acid esters | |
| DE2160946C3 (de) | aminocarbonsäureamide und diese Verbindungen enthaltende Arzneimittel | |
| US3666764A (en) | Spiroindenylpiperidines | |
| DE69121334T2 (de) | DC-89-Derivate als Antitumor-Wirkstoffe | |
| DE2854308A1 (de) | Anticholinergische substanzen mit antisekretorischer wirkung, ihre herstellung und verwendung | |
| SE436885B (sv) | Nya kvartera salter av 3-amino-17a-aza-d-homoandrostan-derivat och forfarande for framstellning derav | |
| EP0173933B1 (de) | 1,6-Naphthyridin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2362754C2 (de) | Cyclopropylalkylaminoreste enthaltende Oxazolinverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2719294A1 (de) | Neue derivate des 1,4-benzodioxans, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| US3592899A (en) | Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels | |
| US5140022A (en) | 3-acyclic or cyclicaminomethyl-17a-lower-alkyl-17a-aza-d-homo-5-alpha-androstanes | |
| US3426017A (en) | Sulfonylurea compounds | |
| EP0180833B1 (de) | 4-Oxo-pyrido[2,3]pyrimidin-Derivate, Verfahren zur deren Herstellung und diese ethaltende Arzneimittel | |
| US3671537A (en) | Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines | |
| HU182298B (en) | Process for preparing new 5,6,8,9-tetrahydro-7h-dibenzo/ /d,f/azonine derivatives and pharmaceutical compositions containing such compounds | |
| DE2221808C2 (de) | Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel | |
| US3505340A (en) | 1-substituted-3-substituted imino-1,5,6,7,8,8a-hexahydro-3-h-thiazolo (3,4-a) pyridines and intermediates therefor | |
| US5229511A (en) | 3-substituted-aminomethyl-3-substituted-oxy-17A-methyl-17A-lower-alkyl-17A-aza-d-homo-5-alpha-androstanes | |
| DE3700825A1 (de) | 8(alpha)-acylaminoergoline, ihre herstellung und verwendung | |
| DE2551235A1 (de) | Aryloxyalkylpiperidine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| NO170630B (no) | Analogifremgangsmaate ved fremstilling av nye, terapeutiskaktive 1-(3-(2-sek.-aminoetoksy)-2-tienyl)-3-fenyl-propanoner og syreaddisjonssalter derav | |
| US3513168A (en) | Indeno (1,2-c) pyridines and 2-guanyl derivatives thereof | |
| EP0462150B1 (de) | Neue aryloxy-alkylamine, deren herstellung und diese enthaltende arzneimittel | |
| DE2259012C3 (de) | 8beta-Pvrimidyl-(2)-aminomethyl-10 a-ergolinderivate und Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7808703-8 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7808703-8 Format of ref document f/p: F |